rasburicase

REMS

Initial management of increased uric acid levels in patients with leukemia, lymphoma, or other malignancies who are being treated with antineoplastics, which are expected to produce hyperuricemia.

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Glucose-6-phosphate dehydrogenase (G6PD) deficiency (↑ risk of severe hemolysis);
Previous allergic reaction, hemolysis, or methemoglobinemia from rasburicase;
OB: Pregnancy;
Lactation: Lactation.

Use Cautiously in:

None reported.

Adv. Reactions/Side Effects ⬆ ⬇

Derm: rash

GI: abdominal pain, constipation, diarrhea, mucositis, nausea, vomiting

Hemat: HEMOLYSIS, METHEMOGLOBINEMIA, neutropenia

Neuro: headache

Resp: respiratory distress

Misc: fever, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS), sepsis

Interactions ⬆ ⬇

Drug-drug:

None reported.

Availability ⬆ ⬇

Lyophilized powder for injection: 1.5 mg/vial; 7.5 mg/vial

Route/Dosage ⬆ ⬇

IV (Adults and Children ): 0.2 mg/kg once daily for 5 days.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

An enzyme that promotes the conversion of uric acid to allantoin, an inactive water-soluble compound.
Produced by recombinant DNA technology.

Therapeutic effects:

Decreased sequelae of hyperuricemia (nephropathy, arthropathy).

Classifications ⬆ ⬇

Therapeutic Classification: antigout agents, antihyperuricemics

Pharmacologic Classification: enzymes

Pharmacokinetics ⬆ ⬇

Absorption: IV administration results in complete bioavailability.

Distribution: Well distributed to tissues.

Metabolism/Excretion: Unknown.

Half-Life: 18 hr.

Canadian Brand Names ⬆ ⬇

Time/Action Profile ⬆ ⬇

(↓ in uric acid)

ROUTE	ONSET	PEAK	DURATION
IV	rapid	unknown	4–24 hr

Patient/Family Teaching ⬆ ⬇

Explain purpose and side effects of medication. Advise patient to read Patient Information before starting therapy.
Advise patient to notify health care provider of all Rx or OTC medications, vitamins, or herbal products being taken and to consult health care provider before taking other medications.
Instruct patient to notify health care provider immediately if difficulty breathing, chest pain, or hives occur.
Rep: May cause fetal harm. Advise women of reproductive potential to notify health care provider if pregnancy is planned or suspected and to avoid breastfeeding during and for 2 wk after last dose.

Pronunciation ⬆ ⬇

Code ⬆

NDC Code

0024- Sanofi-Aventis U.S. LLC
- 0024-5150- Elitek
  - 0024-5150-10- 3 KIT in 1 CARTON (0024-5150-10) / 1 KIT in 1 KIT * 1 mL in 1 VIAL, SINGLE-USE (0024-5154-11) * 1 mL in 1 AMPULE (0024-5152-11)

0024- Sanofi-Aventis U.S. LLC
- 0024-5151- Elitek
  - 0024-5151-75- 1 KIT in 1 CARTON (0024-5151-75) * 5 mL in 1 VIAL, SINGLE-USE (0024-5155-74) * 5 mL in 1 AMPULE (0024-5153-74)

section name header

Indications ⬇